TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Compumedics Limited ( (AU:CMP) ) is now available.
Compumedics Limited has announced a record-breaking fiscal year 2025, characterized by a 22% increase in sales orders and a return to profitability. The company’s strategic focus on the US market and SaaS platforms has driven significant growth, with US sales orders up by 115% and SaaS orders increasing by 49%. Looking ahead, Compumedics aims to scale its business model with new product launches and recurring revenue streams, projecting a revenue of at least $70 million and an EBITDA of approximately $9 million for FY26. The launch of the disposable Somfit in the US and the expansion of the MEG systems into the pediatric market are expected to further enhance the company’s market position and revenue potential.
More about Compumedics Limited
Compumedics Limited operates in the medical technology industry, focusing on sleep and neurology diagnostics. The company offers products and services such as the Somfit and Nexus 360 SaaS platforms, and MEG systems, with a strong market presence in the US, Asia, and Europe.
Average Trading Volume: 45,734
Technical Sentiment Signal: Sell
Current Market Cap: A$48.05M
Learn more about CMP stock on TipRanks’ Stock Analysis page.